Complement-Targeted Therapy to Restrict Glaucoma Progression
About the Research Project
Program
Award Type
Standard
Award Amount
$200,000
Active Dates
July 01, 2019 - June 30, 2022
Grant ID
G2019219
Acknowledgement
Goals
Glaucoma is a disease that degrades vision over time. In the retina, neurons decline and die, despite the immune responses of supporting glial cells. We have developed a new potential treatment that rebalances immune responses and controls glaucoma in old mice, and will define if it may cure patients by treating several experimental models. Also, we will study how dying or surviving neurons interact with glia in the retina.
Summary
This project will determine whether rebalancing immune activation of complement proteins and microglia via ocular gene therapy is neuroprotective in diverse experimental models of adult-onset glaucoma. Progressive vision loss in glaucoma is the result of gradual neuron decline and death in the retina, which is accompanied by dysregulated glial immune responses. My research focuses on understanding the role and function of microglia in glaucoma, and on developing translatable therapeutic strategies by modulating the actions of microglia.
Related Grants
National Glaucoma Research
Improving Glaucoma Care with Agentic AI
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Mark Christopher, PhD
Current Organization
University of California, San Diego
Improving Glaucoma Care with Agentic AI
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Mark Christopher, PhD
Current Organization
University of California, San Diego
National Glaucoma Research
Measuring the Effects of Visual Stimuli on Retinal Blood Vessels and Flow
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Stuart Gardiner, PhD
Current Organization
Good Samaritan Foundation, Legacy Health System
Measuring the Effects of Visual Stimuli on Retinal Blood Vessels and Flow
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Stuart Gardiner, PhD
Current Organization
Good Samaritan Foundation, Legacy Health System
National Glaucoma Research
Activating the Eye’s Own Nitric Oxide to Fight Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Myoungsup Sim, PhD
Current Organization
Duke University School of Medicine
Activating the Eye’s Own Nitric Oxide to Fight Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Myoungsup Sim, PhD
Current Organization
Duke University School of Medicine